E
1.54
-0.08 (-4.94%)
| 前收盘价格 | 1.62 |
| 收盘价格 | 1.63 |
| 成交量 | 7,154,567 |
| 平均成交量 (3个月) | 1,895,771 |
| 市值 | 115,552,760 |
| 预期市盈率 (P/E Forward) | 5.39 |
| 股市价格/股市净资产 (P/B) | 2.62 |
| 52周波幅 | |
| 利润日期 | 14 Nov 2025 |
| 稀释每股收益 (EPS TTM) | -0.040 |
| 总债务/股东权益 (D/E MRQ) | 0.77% |
| 流动比率 (MRQ) | 13.90 |
| 营业现金流 (OCF TTM) | -54.59 M |
| 杠杆自由现金流 (LFCF TTM) | -26.72 M |
| 资产报酬率 (ROA TTM) | -40.10% |
| 股东权益报酬率 (ROE TTM) | -38.15% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Eledon Pharmaceuticals, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
1.5
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | 1.50 |
|
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 1.40% |
| 机构持股比例 | 68.39% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Bvf Inc/Il | 30 Sep 2025 | 6,293,282 |
| Ra Capital Management, L.P. | 30 Sep 2025 | 3,566,338 |
| Siren, L.L.C. | 30 Sep 2025 | 2,072,767 |
| Zimmer Partners, Lp | 30 Sep 2025 | 1,825,000 |
| Wellington Management Group Llp | 30 Sep 2025 | 1,283,939 |
| Sphera Funds Management Ltd. | 30 Sep 2025 | 1,280,233 |
| Ensign Peak Advisors, Inc | 30 Sep 2025 | 1,264,919 |
| Catalio Capital Management, Lp | 30 Sep 2025 | 1,061,132 |
| Blue Owl Capital Holdings Lp | 30 Sep 2025 | 979,912 |
| Sanofi | 30 Sep 2025 | 814,980 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 9.00 (HC Wainwright & Co., 484.42%) | 购买 |
| 中 | 8.50 (451.95%) | |
| 低 | 8.00 (Guggenheim, 419.48%) | 购买 |
| 平均值 | 8.50 (451.95%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 2.05 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Guggenheim | 18 Nov 2025 | 8.00 (419.48%) | 购买 | 1.54 |
| HC Wainwright & Co. | 02 Sep 2025 | 9.00 (484.42%) | 购买 | 2.55 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合